Impact of Intensive Low-Density Lipoprotein Cholesterol-Lowering Therapy on Coronary Artery Plaques in Acute Coronary Syndrome

被引:2
|
作者
Hirai, Keisuke [1 ]
Kawasaki, Tomohiro [1 ]
Soejima, Toshiya [1 ]
Kajiyama, Kimihiro [1 ]
Fukami, Yurie [1 ]
Asada, Satoshi [1 ]
Haraguchi, Kazuki [1 ]
Fukuoka, Ryota [1 ]
Orita, Yoshiya [1 ]
Umeji, Kyoko [1 ]
Koga, Hisashi [1 ]
Yamabe, Hiroshige [1 ]
机构
[1] Shinkoga Hosp, Cardiovasc Ctr, Div Cardiovasc Med, Kurume, Japan
来源
关键词
coronary computed tomography angiography; lipid lowering therapy; coronary artery plaque; LDL CHOLESTEROL; ANGIOGRAPHY; ATORVASTATIN; METAANALYSIS; PERFORMANCE; GUIDELINES; MANAGEMENT; STENOSIS; SOCIETY; JAPAN;
D O I
10.1016/j.amjcard.2023.07.049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute coronary syndrome (ACS) is associated with a high incidence of unstable plaques beyond the culprit lesion, leading to early recurrence of cardiovascular events. Coronary computed tomography angiography (CCTA) can be used to noninvasively observe plaques throughout the coronary arteries. To evaluate the impact of intensive low-density lipopro-tein cholesterol (LDL-C)-lowering therapy on quantitative changes in coronary plaque, assessed using CCTA in a study population with ACS. In total, 81 consecutive patients with ACS who underwent CCTA at discharge and at 1-year follow-up from April 2018 to March 2020 were analyzed. The patients were divided into 2 groups: those who achieved LDL-C <70 mg/100 ml and those who did not. Changes in plaque morphology within and between the 2 groups were compared using CCTA. A total of 198 vessels were analyzed. The calcified plaque volume was significantly increased in the LDL-C <70 group (65.8 & PLUSMN; 80.1 mm3 to 73.6 & PLUSMN; 83.7 mm3, p = 0.007), whereas no significant change was observed in the LDL-C >70 group (106.9 & PLUSMN; 161.7 mm3 to 105.7 & PLUSMN; 137.5 mm3, p = 0.552). Percent change in low-attenuation plaque volume in the LDL <70 group was significantly lower than in the LDL-C >70 group (17.2 & PLUSMN; 90.9% vs 84.4 & PLUSMN; 162.6%, p = 0.020). Receiver oper-ating characteristic curve analysis demonstrated that the target LDL-C level for low-attenuation plaque volume regression was 64 mg/100 ml. In conclusion, noninvasive CCTA demonstrated that intensive LDL-C lowering in high-risk patients with ACS could potentially lead to plaque stabilization. & COPY; 2023 Elsevier Inc. All rights reserved. (Am J Cardiol 2023;204:84-91)
引用
收藏
页码:84 / 91
页数:8
相关论文
共 50 条
  • [41] Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS)
    Afshar, Mehdi
    Pilote, Louise
    Dufresne, Line
    Engert, James C.
    Thanassoulis, George
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (04):
  • [42] Effects of Low-density Lipoprotein Cholesterol on Coronary Artery Calcification Progression According to High-density Lipoprotein Cholesterol Levels
    Lee, Da Young
    Kim, Ji Hyun
    Park, Se Eun
    Park, Cheol-young
    Oh, Ki-won
    Park, Sung-woo
    Rhee, Eun-Jung
    Lee, Won-young
    ARCHIVES OF MEDICAL RESEARCH, 2017, 48 (03) : 284 - 291
  • [43] Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement
    Martin, Gary J.
    Teklu, Meron
    Mandieka, Edwin
    Feinglass, Joe
    CARDIOLOGY RESEARCH AND PRACTICE, 2022, 2022
  • [44] Low-Density Lipoprotein Cholesterol-Independent Effects of Statins on Coronary Artery Disease
    Takagi, Hisato
    Umemoto, Takuya
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (02): : 336 - 336
  • [45] Appropriate Level of Low-Density Lipoprotein Cholesterol for Secondary Prevention of Coronary Artery Disease
    Naito, Ryo
    Miyauchi, Katsumi
    Konishi, Hirokazu
    Tsuboi, Shuta
    Ogita, Manabu
    Dohi, Tomotaka
    Kasai, Takatoshi
    Tamura, Hiroshi
    Okazaki, Shinya
    Isoda, Kikuo
    Daida, Hiroyuki
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2016, 23 (04) : 413 - 421
  • [46] Statin therapy and low-density lipoprotein cholesterol reduction after acute coronary syndrome: Insights from the United Arab Emirates
    Shehab, Abdulla
    Bhagavathula, Akshaya Srikanth
    HEART VIEWS, 2020, 21 (02): : 80 - 87
  • [47] Alirocumab for low-density lipoprotein cholesterol lowering
    Roth, Eli M.
    FUTURE CARDIOLOGY, 2019, 15 (01) : 17 - 29
  • [48] The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease
    Nastasi, Domenico R.
    Moxon, Joseph, V
    Norman, Richard
    Trollope, Alexandra F.
    Rowbotham, Sophie
    Quigley, Frank
    Jenkins, Jason
    Golledge, Jonathan
    JOURNAL OF VASCULAR SURGERY, 2021, 73 (04) : 1396 - +
  • [49] Modification of coronary artery disease progression by cholesterol-lowering therapy: the angiographic studies
    Archbold, RA
    Timmis, AD
    CURRENT OPINION IN LIPIDOLOGY, 1999, 10 (06) : 527 - 534
  • [50] Small dense low-density lipoprotein cholesterol is a useful marker of metabolic syndrome in patients with coronary artery disease
    Nozue, Tsuyoshi
    Michishita, Ichiro
    Ishilbashi, Yuki
    Ito, Shimpei
    Iwaki, Taku
    Mizuguchi, Ichiro
    Miura, Motolhiro
    Ito, Yasulki
    Hirano, Tsutomu
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2007, 14 (04) : 202 - 207